Baxter Succession Plan Set With Kraemer Adding CEO Title Dec. 31
This article was originally published in The Gray Sheet
Baxter President Harry Kraemer's ascension to the additional post of CEO on Dec. 31 will complete a succession plan put in motion in April 1997 with his appointment as president. Baxter announced Feb. 19 that Kraemer, 43, will take over CEO responsibilities from Vernon Loucks at the end of the year. Loucks will remain chairman of Baxter's board of directors.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.